POLYMED1,749.00

Poly Medicure Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersPFIZERRAINBOWONESOURCEKIMSJUBLPHARMAVIJAYAINDGNGRANULESMcap ₹17,728 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations337.3339.6378.1384.8420.0424.2440.8403.2443.9493.7534.5525.4
Other Income14.116.615.016.926.121.824.341.733.926.317.833.4
Total Income351.4356.2393.0401.7446.1446.0465.1444.9477.8519.9552.3558.8
Expenses
+ Cost of Materials Consumed114.2118.7126.6132.6154.9142.0142.0141.1157.1146.2155.1183.9
+ Purchases of Stock-in-Trade2.81.11.40.91.23.32.50.91.21.61.42.7
+ Changes in Inventories4.2-1.73.2-5.2-23.61.22.9-14.7-22.68.021.7-46.8
+ Employee Benefit Expense58.360.469.470.878.177.978.975.188.8115.2126.1126.9
+ Finance Costs2.23.53.13.23.33.32.23.03.06.06.46.5
+ Depreciation & Amortisation16.016.216.219.620.921.521.023.324.928.838.236.3
+ Other Expenses73.570.980.881.894.185.395.194.7104.7111.5119.8133.6
Total Expenses271.3269.1300.8303.7328.9334.5344.6323.3357.1417.2468.8443.0
EBITDA84.290.296.6103.9115.3114.5119.5106.1114.7111.2110.4125.1
EBIT68.274.080.484.394.593.098.482.989.882.472.288.8
Profit
PBT before Exceptional Items80.187.192.298.0117.2111.5120.6121.6120.7102.783.5115.8
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-6.80.00.0
Pretax Income80.187.192.298.0117.2111.5120.6121.6120.795.983.5115.8
+ Current Tax17.220.020.222.725.024.223.822.127.526.525.428.2
+ Deferred Tax1.62.93.91.75.53.87.27.82.40.3-5.33.9
Tax Expense18.822.824.124.430.528.031.029.929.926.820.232.0
+ Share of Associates & JVs0.80.70.20.40.81.72.31.31.01.71.71.6
Net Income62.265.068.474.087.585.291.893.191.870.865.085.3
+ Net Income — Continuing Ops61.464.368.173.686.783.589.691.890.869.163.383.7
+ Other Comprehensive Income-0.80.2-0.1-1.40.1-0.20.1-0.7-0.222.524.9-0.0
Total Comprehensive Income61.465.368.372.787.585.092.092.491.693.389.985.2
Net Income to Common62.265.068.474.087.585.291.893.191.870.966.386.0
Minority Interest0.00.00.00.00.00.00.00.0-0.0-0.1-1.3-0.8
Per Share
Basic EPS6.486.787.127.719.018.488.929.199.067.006.548.49
Diluted EPS6.476.777.127.719.018.488.929.179.066.996.538.48
Other Comprehensive Income — detail
+ Other Comprehensive Income0.1-0.7-0.222.524.9-0.0
+ Items NOT to be Reclassified to P&L-1.10.1-0.0-1.7-0.50.2-0.1-1.20.30.30.8-0.9
+ Tax on Items NOT to be Reclassified-0.0-0.30.10.10.2-0.2
+ Tax on Items NOT to be Reclassified — alt tag-0.30.0-0.0-0.4-0.10.1
+ Items to be Reclassified to P&L-0.00.2-0.1-0.10.4-0.40.20.2-0.522.324.30.6
Comprehensive Income — Owners of Parent61.465.3-0.172.787.585.092.092.491.622.591.286.0
Comprehensive Income — Non-controlling Interests0.00.00.00.00.00.00.00.0-0.00.0-1.3-0.8
Per Share — as-filed variants
Basic EPS — Continuing Operations6.486.787.127.719.018.488.929.199.067.006.548.49
Diluted EPS — Continuing Operations6.476.777.127.719.018.488.929.179.066.996.538.48
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit216.1221.6246.9256.5287.5277.7293.4276.0308.2337.9356.3385.6
Gross Margin %64.0665.2465.3066.6768.4565.4666.5668.4569.4468.4566.6773.40
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)80.187.192.298.0117.2111.5120.6121.6120.7102.783.5115.8
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-6.80.00.0
Net Income Adj (tax-effected)62.265.068.474.087.585.291.893.191.875.765.085.3
EPS Adj6.486.787.127.719.018.488.929.199.067.486.548.49
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.005.005.005.005.005.005.005.005.00
Paid Up Equity Capital48.048.048.048.050.650.750.750.750.750.750.750.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.